- Kane Biotech (KNE) has closed a private placement for gross proceeds of $1 million
- The company issued 10,000,000 common shares at a price of $0.10 per share
- Net proceeds will be used for general working capital purposes
- Kane Biotech is a biotechnology company focused on preventing and removing microbial biofilms
- Kane Biotech Inc. (KNE) opened trading at C$0.10 per share
Kane Biotech (KNE) has closed its previously announced private placement for gross proceeds of $1 million.
The company issued 10,000,000 common shares at a price of $0.10 per share.
President and Chief Executive Officer, Marc Edwards acquired a total of 3,100,000 common shares.
Net proceeds will be used for general working capital purposes.
The securities issued are subject to a four-month hold period ending on September 17, 2022.
The company paid $6,000.00 in finder’s fees.
Kane Biotech is a biotechnology company focused on preventing and removing microbial biofilms.
Kane Biotech Inc. (KNE) opened trading at C$0.10 per share.
